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Abstract
Background: Viral infections and the burden of high-grade intraepithelial neoplasias (HIN) and invasive carcinomas
(IC) associated to infections by human papillomavirus (HPV) types may be prevented by type-specific anti-HPV
vaccines. This study determined the prevalence of HPV types in non-cervical HIN and IC diagnosed from 1999 to
2011 at a general hospital in San Luis Potosí, Mexico.
Methods: Review of the 67 formaldehyde-fixed paraffin-embedded non-cervical specimens initially diagnosed as
HIN (n = 28) or IC (n = 39) confirmed the presence of tumor tissue in 63 of them and changed the diagnosis of 24
from HIN to low-grade intraepithelial neoplasias, that were excluded from the study. HPV DNA was detected with
the SPF10-DNA enzyme immunoassay in the 39 cases included, and viral types in the HPV-positive tumors were
identified with the INNO-LiPA linear probe array.
Results: Among the cases included, four HIN were located in the vagina (n = 3) and vulva (n = 1), and 35 IC in the
oral cavity (n = 19), penis (n = 8), vagina (n = 7) and vulva (n = 1). There were 13 HPV-positive cases from the vagina
(n = 7), vulva (n = 1), penis (n = 1) and oral cavity (n = 1). The viral types identified were the high-risk types HPV16
in the vagina (n = 3) and vulva (n = 3), HPV45 in the vagina (n = 2), HPV59 in the vagina (n = 1) and penis (n = 1),
HPV33 in the vagina (n = 1),and HPV35 in the tongue(n = 1); and the low-risk types HPV54 in the vagina (n = 1), and
HPV11 in the vulva (n = 1).
Conclusions: Five high-risk viral types (HPV16, 45, 59, 33 and 35) and two low-risk types (HPV11 and 54) infect one
third of the non-cervical HIN and IC included. Most infections are by a single HPV high-risk type, the most prevalent
one being HPV16. Vagina is the most frequent location of the HPV-positive tumors. Vaccination against HPV16 and
HPV18 could have prevented around half of the HPV-positive tumors.
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Background
The order of prevalence of high-risk HPV types associ-
ated to cervical carcinomas around the world is HPV16,
18, 31, 33, 35, 45, 52 and 58 [1]. It is similar for cervical
carcinomas in Mexico [2–4] and abnormal cervical
scrapes in the Mexican states of San Luis Potosí and
Guanajuato [5].
Persistent infection with high-risk HPV types is neces-
sary for neoplastic transformation of the normal cervical
epithelium to high-grade intraepithelial neoplasia (HIN)
and its progression to invasive carcinoma (IC) [6–8]. Viral
infection and the burden of neoplastic lesions may be
reduced through prophylactic HPV vaccination [9], but
HPV type distribution has to be determined to establish
health care policies and vaccination programs in each
area [1, 10].
Association of HPV types to non-cervical carcinomas
has been demonstrated in recent years. HPV16, 33 and
18 are the most prevalent types in vulvar carcinomas
[11, 12], HPV16, 18, 31 and 33 in vaginal and anal car-
cinomas [13], and HPV16 in oral carcinomas [14]. In
Mexico, Flores de la Torre et al. [15] found HPV DNA
in nearly half of 117 head and neck carcinomas with
HPV16 as the major viral type.
In this study we identified the HPV types present in
HIN and IC from the oral cavity, penis, vagina and vulva
diagnosed in a 12-year period at the largest general hos-
pital of San Luis Potosí, to estimate the effect that anti-
HPV vaccination could have had to prevent them.
Materials and methods
Study design and population
The protocol of this work was based on that of a mul-
ticentric study designed by the ICO and approved by
the Delft Diagnostic Laboratory (DDL) [1]. The study
protocol and consent procedure were approved by the
Research and Ethics Committees of the Hospital Cen-
tral Ignacio Morones Prieto and the Institut Català
d’Oncologia (ICO). Like similar studies, its implemen-
tation did not require informed consent from the pa-
tients, who are not identified by name in accordance
with the Mexican General Health Law.
The study considered the 67 non-cervical tumors
whose formalin-fixed paraffin-embedded (FFPE) blocks
were recovered. The initial IC and HIN diagnoses were
performed between 1999 and 2011 at the Pathology
Department of Hospital Central Ignacio Morones Prieto.
Selection and analysis of the cases included
The cases included were those in which the ICO Path-
ology Reference Laboratory confirmed the presence of
tumor tissue and made the final (IC or HIN) histopatho-
logical diagnoses. FFPE blocks from the 67 cases were an-
alyzed by the sandwich method based on five sections
[1]. Section 1 (negative control), 5 μm thick, was ob-
tained from a virgin paraffin block and placed in a
tube. The following four serial sections were from the
paraffin block of an acceptable case (i.e., containing
tumor tissue); sections 2 and 5, 3 μm thick, were
placed on individual microscope slides; sections 3 and
4, 5 μm thick, were placed in each of two tubes. In
order to avoid cross contamination the microtome
blade was replaced after obtaining the sections from
each tumor block. Sections on the slides were stained
with hematoxylin-eosin and subjected to histopatho-
logical review; DNA was extracted from sections 1
and 3 or 5 for HPV detection and typing.
The cases were excluded if slides 2 and 4 did not
contain tumor tissue. When only the first slide con-
tained tumor tissue, DNA extracted from tube 1 was
amplified using the SPF10 (short PCR fragment gener-
ated with 10 oligonucleotides) method followed by
DNA enzyme immunoassay (DEIA) [12] to detect HPV
sequences. DNA extracted from tube 2 was amplified
when tumor tissue was found in both slides or only in
the second one [1].
DNA extraction and HPV detection and typing
Each 5 μm section from a paraffin block with tumor tis-
sue was mixed with 250 μL of proteinase K (1 mg/mL)
dissolved in 10 mM Tris–HCl, 1 mM EDTA (pH 8.0)
and 0.5 % Tween-20, and incubated overnight at 60 °C.
Proteinase K was then inactivated by heating at 95 °C
for 10 min. To determine the presence of HPV DNA,
1 μL of the supernatant from each section treated with
proteinase K was added to the SPF10-DEIA PCR mix
under the conditions described by Kleter et al. [17].
Samples of the HPV-positive DNA extracts were ana-
lyzed with the INNO-LiPA (linear probe array) on-strip
reverse hybridization method (Innogenetics, DDL) which
identifies 25 of the 40 anogenital HPV types [18].
Results
Stages of the study
The study was carried out in five steps (Fig. 1): 1) 67
formalin-fixed paraffin-embedded (FFPE) blocks from
non-cervical tumors with initial HIN or IC diagnoses
were retrieved from the Pathology Department of Hos-
pital Central Ignacio Morones Prieto; 2) sections were
obtained by the sandwich method and final diagnoses
were performed at the ICO Pathology Reference Labora-
tory; 3) cases with final IC or HIN histopathological
diagnoses were included, and those lacking tumor tissue
or with final diagnoses of low-grade intraepithelial neo-
plasia (LIN) were excluded; 4) SPF10-DEIA was per-
formed to identify HPV-positive and -negative tumors in
the cases included; 5) viral types in the HPV-positive
cases were identified with the INNO-LiPA assay.
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Histopathological diagnosis and case selection
Initial diagnoses of the 63 acceptable cases were 28 HIN
and 35 IC (Table 1). There were 27 HIN located in female
genitalia (25 in the vagina, two in the vulva) and one in
the anus. Nineteen IC were located in the oral cavity (nine
in the larynx, six in the tongue, two in the palate, one in
the jaw, one in the pharynx), eight in the penis, eight in fe-
male genitalia (seven in the vagina, one in the vulva).
Review of the slides showed that four FFPE blocks
lacked tumor tissue and led to the final diagnoses which
determined the inclusion or exclusion of the tumor-
containing specimens. Twenty-four cases with initial
HIN diagnoses changed to low-grade intraepithelial neo-
plasia (LIN) and therefore excluded (22 from the vagina,
one from the vulva and one from the anus) (Table 1).
Agreement between the initial and final diagnoses for
IC was 100 % (35/35), but only 14.3 % (4/28) for HIN
(Table 1). The 39 cases included were four HIN (three
from the vagina, one from the vulva) and all 35 IC from
the already mentioned locations.
HPV detection and typing
Fourteen of the cases included were HPV-positive (35.9 %),
comprising 10 IC (six from the vagina, one from the vulva,
one from the penis and one from the tongue), and four
HIN (three from the vagina and one from the vulva).




HIN IC LIN HIN IC
Anogenital Vulva 2 1 1 1 1
Vagina 25 7 22 3 7
Anus 1 0 1 0 0
Penis 0 8 0 0 8
Subtotal 28 16 24 4 16
Oral Larynx 0 9 0 0 9
Tongue 0 6 0 0 6
Palate 0 2 0 0 2
Jaw 0 1 0 0 1
Pharynx 0 1 0 0 1
Subtotal 0 19 0 0 19
Total 28 35 24 4 35
aIC invasive carcinoma, HIN high-grade intraepithelial neoplasia, LIN low-grade
intraepithelial neoplasia
bThe study excluded the 24 cases with final LIN diagnoses and included the
39 cases with final HIN and IC diagnoses
Initial diagnoses (n=67)
• Invasive carcinoma (IC, n=39)
• High-grade intraepithelial neoplasia (HIN, n=28)





• No tumor tissue (n=4)
Cases excluded (n=28)
• LIN (n=24)




HPV detection by SPF10-DEIA (n=39)
HPV-negative (n=26) HPV-positive (n=13)
HPV types by INNO-LiPA (n=13)
Fig. 1 Stages of the study. Histopathological review showed that four of the 67 initial paraffin blocks lacked tumor tissue and were discarded.
Of the 63 acceptable paraffin blocks, 28 were excluded because their initial diagnoses changed from HIN to LIN. DNA extracted from the paraffin
blocks of the 39 cases included (35 IC and four HIN) was subjected to the SPF10-DEIA assay. The 13 HPV-positive cases were further analyzed with
the INNO-LiPA assay to identify the viral types
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Seven viral types were identified with the INNO-LiPA
assay applied to the HPV-positive cases (Table 2): five of
high-risk (HPV16, 45, 59, 33 and 35) and two of low-risk
(HPV11 and 54). The most prevalent type was HPV16,
present in six cases (two vaginal and one vulvar IC, and
three vaginal HIN), followed by HPV45 in two vaginal
IC, and HPV59 in two IC (one of the vagina and one of
the penis). There were five cases with each of the follow-
ing types: HPV33 (vaginal IC), HPV35 (lingual IC),
HPV54 (vaginal IC) and HPV11 (vulvar HIN) (Table 2).
Twelve of the 13 HPV-positive cases (92.3 %) had
DNA from a single high-risk type. The only vaginal IC
had a double infection by a high-risk and a low-risk type
(HPV16 and HPV59). The only vulvar HIN had the low-
risk HPV11 type.
Discussion
The SPF10-DEIA-INNOLiPA assay used in this work is
highly sensitive and specific for HPV DNA detection
and typing. It has been used in several multicenter stud-
ies [1, 12] because it generates 65-base-pair-long viral
amplicons from the DNA extracted from FFPE sections,
whose fixation and manipulation damage DNA and pre-
vent the generation of longer amplicons [17, 19].
The presence of tumor tissue was confirmed in 63 out
of the 67 original paraffin blocks and the study included
only 39 cases with final HIN or IC diagnoses because
the initial diagnoses changed from HIN to LIN in 24
cases. The initial and final diagnoses coincided in all the
35 IC cases included, whereas 24 of the 28 initial HIN
cases changed to LIN and were excluded. Since prema-
lignant vaginal squamous epithelial lesions are classified
as grade 1 (LIN), grade 2 and grade 3 (the last two
grades synonymous with HIN) [20], the diagnostic dis-
cordance appears to result from having included grade 2
and 3 lesions in the group of initial diagnoses and grade
3 lesions in the group of final diagnoses. On the other
hand, the exclusion of 24 initial HIN cases —22 from
the vagina— improved the quality of the study.
The more stringent diagnostic criteria of the ICO Path-
ology Reference Laboratory for preinvasive neoplastic le-
sions resulted in the inclusion of all the initially diagnosed
IC but only 14.3 % of the initially diagnosed HIN.
LIN samples were excluded from the study because HPV
infections are spontaneously cleared in most of them, while
they persist in HIN and IC [21]. Most of the cases included
were IC (89.7 %) with the following anatomic locations:
48.7 % in the oral cavity (larynx 23.1 %, tongue 15.4 %,
palate 5.1 %, jaw 2.6 %, pharynx 2.6 %); 41.0 % in male and
female genitalia (penis 20.5 %, 17.9 % vagina, vulva 2.6 %).
The HIN cases included were located in female genitalia
(10.3 %): vagina (7.7 %) and vulva (2.6 %).
Only one third of the cases included were HPV-positive.
Nine were IC: six from the vagina, one from the vulva,
one from the penis and one from the oral cavity; four were
HIN: three from the vagina and one from the vulva. These
results are consistent with those of several multicenter
studies; Kreimer et al. [22] showed an HPV prevalence
around 25 % in head and neck carcinomas, De Vuyst et al.
[13] found prevalences of 85.3 % for IC and 40.4 % for
HIN in the vulva and of 90.1 % for IC and 69.9 % for HIN
in the vagina, and Van Aar et al. [23] of 16 to 32 % in
penile carcinomas.
Seven viral types were identified in the HPV-positive
cases: five of high risk (HPV16, 45, 59, 33, and 35), and
two of low-risk (HPV11 in a vulvar HIN and HPV54 in
a vaginal IC). Infections with only one low-risk HPV
type have been shown in vulvar IC (HPV6, 26 or 61) by
Sutton et al. [11], and in anal and perineal HIN and IC
(HPV6 and 11) by Cornall et al. [24].
The most prevalent viral type is HPV16 (46.1 %),
followed by HPV45 and 59 (15.4 % each). These data are
consistent with HPV16 being the most prevalent type in
vulvar, vaginal, anal and oral carcinomas [13, 22].
Table 2 Viral types identified in the HIN and IC cases analyzed for HPV
Cases HIN IC Total
Vagina Vulva Larynx Tongue Palate Jaw Pharynx Penis Vaginaa Vulva
Analyzed for HPV, n (%) 3 (7.7) 1 (2.6) 9 (23.1) 6 (15.4) 2 (5.1) 1 (2.6) 1 (2.6) 8 (20.5) 7 (17.9) 1 (2.6) 39 (100.0)
HPV type detected, n (%)
16 3 0 0 0 0 0 0 0 2 1 6 (15.4)
59 0 0 0 0 0 0 0 1 1 0 2 (5.1)
45 0 0 0 0 0 0 0 0 2 0 2 (5.1)
54 0 0 0 0 0 0 0 0 1 0 1 (2.6)
35 0 0 0 1 0 0 0 0 0 0 1 (2.6)
33 0 0 0 0 0 0 0 0 1 0 1 (2.6)
11 0 1 0 0 0 0 0 0 0 0 1 (2.6)
HPV positive cases, n (%) 3 (7.7) 1 (2.6) 0 (0.0) 1 (2.6) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.6) 7 (17.9) 1 (2.6) 14 (35.9)
aA vaginal IC was the only case with a double infection, by HPV16 and HPV59
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HPV35 was identified in the only oral IC despite the
fact that HPV18 is often associated with non-cervical
carcinomas [25] and HPV16 is the most prevalent in
oral carcinomas [14].
A single viral type was detected in 12 of the 13 HPV-
positive tumors (92.3 %), and two types in the remaining
one. This finding suggest that most infections by a single
HPV type are linked to tumor development and agree
with a multicenter study which demonstrated single
infections in 93 % in cervical and non-cervical HPV-
positive carcinomas [1].
The small sample size resulting from the low preva-
lence of the non cervical carcinomas is an obvious limi-
tation of the study, which includes the corresponding
tumors diagnosed for over a decade at a large Mexican
hospital, identifies the HPV-positive tumors and the viral
types to which they can be attributed, and calculates the
ones could that have been prevented by anti-HPV
vaccination.
The 13 HPV-positive tumors were, in descending order
of frequency, nine vaginal, two vulvar, one penile, and one
lingual. Assuming that the divalent, quadrivalent and non-
avalent HPV vaccines induce complete protection but only
against the viral types to which they are directed, the diva-
lent and quadrivalent vaccines could have prevented seven
tumors (~54 %) and the nonavalent vaccine 11 tumors
(~85 %), mostly vaginal and vulvar.
Conclusions
Final histopathological diagnoses leading to the inclu-
sion or exclusion of non-cervical tumors agreed with
all the initial IC diagnoses but only one-seventh of the
initial HIN diagnoses. Five high-risk viral types
(HPV16, 45, 59, 33 and 35) and two low-risk types
(HPV11 and 54) infect one third of the tumors in-
cluded. Twelve of the 13 HPV-positive tumors (92.3 %)
are infected by a single viral type. The most prevalent
type is HPV16 (46.1 %), followed by HPV45 and 59
(15.4 % each). Vagina is the predominant location of
the HPV-positive tumors. Vaccination with the diva-
lent, quadrivalent or nonavalent HPV vaccines in this
region could have prevented from half to over two
thirds of the HPV-positive non-cervical tumors, mostly
vaginal.
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